Risk Factors and Immunity in a Nationally Representative Population following the 2009 Influenza A(H1N1) Pandemic
Open Access
- 14 October 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (10), e13211
- https://doi.org/10.1371/journal.pone.0013211
Abstract
Understanding immunity, incidence and risk factors of the 2009 influenza A(H1N1) pandemic (2009 H1N1) through a national seroprevalence study is necessary for informing public health interventions and disease modelling. We collected 1687 serum samples and individual risk factor data between November-2009 to March-2010, three months after the end of the 2009 H1N1 wave in New Zealand. Participants were randomly sampled from selected general practices countrywide and hospitals in the Auckland region. Baseline immunity was measured from 521 sera collected during 2004 to April-2009. Haemagglutination inhibition (HI) antibody titres of ≥1∶40 against 2009 H1N1 were considered seroprotective as well as seropositive. The overall community seroprevalence was 26.7% (CI:22.6–29.4). The seroprevalence varied across age and ethnicity. Children aged 5–19 years had the highest seroprevalence (46.7%;CI:38.3–55.0), a significant increase from the baseline (14%;CI:7.2–20.8). Older adults aged ≥60 had no significant difference in seroprevalence between the serosurvey (24.8%;CI:18.7–30.9) and baseline (22.6%;CI:15.3–30.0). Pacific peoples had the highest seroprevalence (49.5%;CI:35.1–64.0). There was no significant difference in seroprevalence between both primary (29.6%;CI:22.6–36.5) and secondary healthcare workers (25.3%;CI:20.8–29.8) and community participants. No significant regional variation was observed. Multivariate analysis indicated age as the most important risk factor followed by ethnicity. Previous seasonal influenza vaccination was associated with higher HI titres. Approximately 45.2% of seropositive individuals reported no symptoms. Based on age and ethnicity standardisation to the New Zealand Population, about 29.5% of New Zealanders had antibody titers at a level consistent with immunity to 2009 H1N1. Around 18.3% of New Zealanders were infected with the virus during the first wave including about one child in every three. Older people were protected due to pre-existing immunity. Age was the most important factor associated with infection followed by ethnicity. Healthcare workers did not appear to have an increased risk of infection compared with the general population.This publication has 26 references indexed in Scilit:
- Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USAPLOS ONE, 2010
- A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009Australian and New Zealand Journal of Public Health, 2010
- Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from CanadaPLoS Medicine, 2010
- Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 InfluenzaPLoS Currents, 2010
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusThe New England Journal of Medicine, 2009
- Immunity to challenge in volunteers vaccinated with an inactivated current or earlier strain of influenza A(H3N2)Epidemiology and Infection, 1978
- Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccinesEpidemiology and Infection, 1977
- Dose-Response Relationship after Immunization of Volunteers with a New, Surface-Antigen-Adsorbed Influenza Virus VaccineThe Journal of Infectious Diseases, 1977
- Prevalence of Antibody to Current Influenza Viruses and Effect of Vaccination on Antibody ResponseBMJ, 1972
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972